Cetera Advisor Networks’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Cetera Advisor Networks’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-13,400	Closed	-$65K	–	2168
2021 Q3	$65K	Hold	13,400	–	–	﹤0.01%	1922
2021 Q2	$86K	Buy	+13,400	New	+$88.4K	﹤0.01%	1856

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Cetera Advisor Networks's MACK Position: Q4 2021 in Review

Cetera Advisor Networks sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2021, closing a stake of 13,400 shares — an estimated $65K sold.

Cetera Advisor Networks first reported a position in MACK in Q2 2021 and held it in 2 quarters. The position peaked at $86K in Q2 2021. 38 funds tracked by Wall St. Rank hold MACK as of Q4 2021.

Cetera Advisor Networks reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Cetera Advisor Networks sold 13,400 Merrimack Pharmaceuticals, Inc. shares in Q4 2021, an estimated $65K.
Cetera Advisor Networks first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
Cetera Advisor Networks's Merrimack Pharmaceuticals, Inc. position peaked at $86K in Q2 2021.
38 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2021.

Based on Cetera Advisor Networks's 13F filing for Q4 2021, filed 14 Feb 2022.